IgG4相关性疾病的管理
本文综述了IgG4相关性疾病的管理策略。该病具有强烈器官倾向性,早期识别至关重要,因尽管高度可治,但晚期未诊断可致严重器官损害甚至死亡。糖皮质激素有效但长期使用存在问题,尤其在中老年患者中常致胰腺功能障碍。对病理生理学的深入理解提示生物制剂等靶向治疗可能改变管理方式。
要点
- 早期识别IgG4相关性疾病至关重要,因晚期未诊断可致严重器官损害甚至死亡。
- 糖皮质激素有效,但长期使用在中老年患者中存在问题,常致胰腺功能障碍。
- 对病理生理学的理解提示生物制剂等靶向治疗可能改变管理方式。
核心结论
- IgG4相关性疾病高度可治,但早期识别至关重要,因晚期未诊断可致严重器官损害甚至死亡。
- 糖皮质激素有效但长期使用存在问题,尤其在中老年患者中常致胰腺功能障碍。
- 对病理生理学的深入理解提示生物制剂等靶向治疗可能深刻改变该病的管理方式。
研究设计与样本
- 本文为综述,回顾了IgG4相关性疾病的临床、病理和影像学特征及管理策略。
主要发现
- IgG4相关性疾病具有强烈器官倾向性,其临床表现日益为全科医生和专科医生所熟悉。
- 该病性质隐匿,常使诊断具有挑战性,是当前时代其他疾病的伟大模仿者之一。
- 糖皮质激素是有效治疗,但长期使用在中老年患者中存在问题,且该病常致胰腺功能障碍。
- 尽管该病被认识较晚,但对其病理生理学的理解已相当深入。
临床怎么用
- 临床医生应早期识别IgG4相关性疾病,避免晚期诊断导致严重器官损害甚至死亡。
- 使用糖皮质激素治疗时需权衡长期使用风险,尤其关注中老年患者的胰腺功能障碍。
- 基于病理生理学理解,可考虑生物制剂等靶向治疗,按患者临床表型定制特异性疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgG4-related disease was unrecognised as a unified disease entity until this century, yet in a short period of time the disease has been appreciated to have a worldwide distribution, and its clinical, pathological, and radiological features have been described in considerable detail. The disease has strong organ predilections, and many of the clinical presentations of disease are increasingly familiar to both generalists and specialists. Early recognition of IgG4-related disease is crucial because although the disease is highly treatable, it can lead to serious organ damage and even death if undiagnosed until advanced stages. Its indolent nature often makes diagnosis challenging, and IgG4-related disease is one of the great mimickers of other diseases in the current era. Glucocorticoids are an effective treatment for IgG4-related disease, but their long-term use is problematic in a disease that frequently affects middle-aged to elderly individuals and often leads to pancreatic dysfunction. Our understanding of the pathophysiology of the disease is surprisingly advanced given the relatively recent recognition of this condition. Insights into disease pathophysiology offer the possibility of a variety of targeted treatment approaches. Looking ahead, biological therapies could profoundly alter the way in which IgG4-related disease is managed, permitting the use of specific therapies that are tailored to patients' clinical phenotypes.
引用
- Zhang W, Stone JH. Management of IgG4-related disease. Lancet Rheumatol. 2019. PMID: 38229361. doi:10.1016/S2665-9913(19)30017-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。